Home › Search
Search
314 results for "lecanemab".
Research summaries 285
Showing the best 200 of 285, 91–100, page 10 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/lecanemab-treatment-for-alzheimer-s-disease-of-varying-severities-and-41070709
… biomarker dynamics of Lecanemab in Chinese patients with Alzheimer's disease (AD). Methods A multi-center prospective cohort study enrolled 68 AD patients. Cognitive scales and plasma biomarkers were assessed at baseline (V0), …
-
Research summaries · alzhub.org/study/lecanemab-aducanumab-and-gantenerumab-binding-profiles-to-different-36253511
… binding properties of lecanemab, aducanumab, and gantenerumab to different Aβ species with inhibition ELISA, immunodepletion, and surface plasmon resonance. All three antibodies bound monomers with low affinity. However, …
-
Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in CanadaResearch summary
Research summaries · alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-d453d052
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). In contrast, Aducanumab …
-
Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in CanadaResearch summary
Research summaries · alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-08ace6f7
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia). In contrast, Aducanumab …
-
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilanceResearch summary
Research summaries · alzhub.org/study/long-term-surveillance-of-the-anti-amyloid-monoclonal-antibody-40217276
The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into traditional approval in June …
-
Research summaries · alzhub.org/study/population-pharmacokinetic-pharmacodynamic-analyses-of-amyloid-36165093
Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) …
-
Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/re-evaluation-of-the-efficacy-and-safety-of-anti-a-monoclonal-40308765
… monoclonal antibodies (Lecanemab/Donanemab) in the treatment of early Alzheimer's disease (AD) and to provide evidence for rational clinical use. Methods We searched databases including PubMed, Embase, Cochrane, Web of Science, …
-
Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experienceResearch summary
Research summaries · alzhub.org/study/real-world-safety-and-implementation-challenges-of-lecanemab-therapy-42449395
Lecanemab, an amyloid-targeting monoclonal antibody, was recently approved for early symptomatic Alzheimer's disease in South Korea. Asians were underrepresented in prior trials, and real-world data from Korea remain scarce, …
-
Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature reviewResearch summary
Research summaries · alzhub.org/study/two-cases-of-amyloid-related-imaging-abnormalities-aria-following-40624486
… patients treated with lecanemab. Methods We report two clinical cases of ARIA following lecanemab treatment and analyze the imaging features, risk factors, and management strategies of ARIA based on the latest literature. Results …
-
Research summaries · alzhub.org/study/mechanism-of-action-and-clinical-trial-results-of-lecanemab-leqembi-38692883
Lecanemab is a humanized monoclonal antibody directed against human soluble amyloid-β aggregates. It was developed for the treatment of early Alzheimer's disease (mild cognitive impairment or mild dementia stage of Alzheimer's …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.